Reviewer's report

Title: Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life. A cross-sectional study

Version: 4  Date: 11 December 2014

Reviewer: Hisao Tachibana

Reviewer's report:

This is a well-conducted study and results are understandable. I have some questions.

1) Table 2: How would you explain about the insignificant difference on PDQ-8 SI between patients with and without insufficient efficacy only in the Yahr 4 stage? You showed significant difference on PDQ-8SI between patients with and without insufficient efficacy even for patients with Yahr 1 stage. Additionally, in conclusion (abstract), you describe "greater awareness of insufficient funding then be taken". This is a reasonable comment. Many patients feel insufficient drug efficacy even in the early stage of PD patients. However, most doctors do not increase the anti-PD drugs to maximal doses to remove all symptoms, because of the possible side effects in the future, although they understand insufficient drug efficacy in the early stage of PD patients. Would you explain about "appropriate action" in such occasion?

1) Table 3: Could you show us which factor is more important on the QOL between only in the daytime zone and only in the time zone of sleeping and early morning without daytime inefficiency?

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.